



## PCSK9 Inhibitors: Georgia

### PCSK9 Inhibitors

PCSK9 inhibitors are designed for patients with extremely high LDL, or “bad,” cholesterol. The drugs work by preventing the PCSK9 protein from destroying a receptor on the liver that clears bad cholesterol. The receptor “lives” longer, clearing more LDL cholesterol for the patient.

PCSK9 inhibitors are approved by the Food and Drug Administration to treat:

- **Heterozygous familial hypercholesterolemia**, an inherited condition that causes high levels of LDL cholesterol
- **Clinical atherosclerotic cardiovascular disease**, such as heart attacks or strokes.

### Analysis of Health Plan Coverage & Access


A national data supplier reviewed PCSK9 inhibitor claims for managed care organizations in Georgia from August 6, 2015 to July 21, 2016.

#### Key Georgia Findings



Rejection Rate:

**50%**



Total rejections:

**1,515**



Total appeals:

**333**

Of health plans that received at least 50 claims for PCSK9 inhibitors, the following had **the highest rates of rejections**:

Federal Employee Benefit Plan **84%** | Express Scripts **73%**  
Anthem **73%** | Georgia State Health Benefit Plan **71%**

The following had **the lowest rates of rejection**:

CVS Health **55%** | United Health Group **54%**  
Humana Health Plan **34%** | Aetna US Healthcare **27%**

The following table details claims data for the Georgia managed care organizations that received at least 50 claims for PCSK9 inhibitors.

MANAGED CARE ORGANIZATION	Rejection %	Total Claims	Approvals	Rejections	Reversals
Federal Employee Benefit Plan	84.72%	72	10	61	1
Express Scripts	73.71%	175	38	129	8
Anthem	73.49%	83	13	61	9
Georgia State Health Benefit Plan	71.62%	74	21	53	0
Tricare Military Health SVC Sys	70.00%	80	17	56	7
Cigna Healthcare	58.78%	148	45	87	16
CVS Health	55.08%	256	75	141	40
United Health Group	54.44%	597	199	325	73
Humana Health Plan	34.88%	774	336	270	168
Aetna US Healthcare	27.88%	373	195	104	74

*Data source: National data supplier; Medicare, Medicaid managed care and commercial plans; August 6, 2015-July 21, 2016.*



The Institute for Patient Access is a physician led nonprofit 501(c)(3) research organization promoting the benefits of the physician-patient relationship in the provision of quality healthcare.

